- Home
- CBUS vs GNLX Comparison
CBUS vs GNLX Comparison
Compare CBUS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBUS | GNLX |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.1M | 113.6M |
| IPO Year | 2017 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CBUS | GNLX |
|---|---|---|
| Price | $1.48 | $3.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $9.00 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 411.8K | 152.2K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.33 | 9.47 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,639,000.00 | $8,000.00 |
| Revenue This Year | $112.72 | N/A |
| Revenue Next Year | $83.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $2.29 |
| 52 Week High | $4.19 | $8.54 |
Technical Indicators
Market Signals| Indicator | CBUS | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 43.44 | 62.78 |
| Support Level | $1.43 | $3.03 |
| Resistance Level | $1.50 | $3.70 |
| Average True Range (ATR) | 0.11 | 0.19 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 54.79 | 76.33 |
Price Performance
Historical ComparisonAbout CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.